The artifcial pancreas: How sweet engineering will solve bitter problems

Journal of Diabetes Science and Technology

Volumn 1, Issue 1, 2007, Pages 72-81

  Klonoff, David C ^a  

^a DIABETES RESEARCH INSTITUTE   (United States)

Author keywords

Artifcial; Closed loop; Control; Diabetes; Glucose; Pancreas

Indexed keywords

EID: 34248162815     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680700100112     Document Type: Review

References (90)

1. Hashiguchi Y, Sakakida M, Nishida K, Uemura T, Kajiwara K, Shichiri M.: Development of a miniaturized glucose monitoring system by combining a needle-type glucose sensor with microdialysis sampling method. Long-term subcutaneous tissue glucose monitoring in ambulatory diabetic patients. Diabetes Care. 1994;17:387-396.
2. Shichiri M, Sakakida M, Nishida K, Shimoda S.: Enhanced, simplifed glucose sensors: long-term clinical application of wearable artifcial endocrine pancreas. Artif Organs. 1998;22:32-42.
3. Kalatz B, Hoss U, Gessler R, Sternberg F, Lohmann S, Salgado M et al.: Development of algorithms for feedback-controlled subcutaneous insulin infusion with insulin lispro. Acta Diabetol. 1999;36:215.
4. Freckmann G, Kalatz B, Pfeiffer B, Hoss U, Haug C.: Recent advances in continuous glucose monitoring. Exp Clin Endocr Diab. 2001;109:S347-S357.
5. Chee F, Fernando TL, Savkin AV, Van Heeden V: Expert PID control system for blood glucose control in critically ill patients. IEEE Trans Inf Technol Biomed. 2003;7:419-25.
6. Kan S, Onodera H, Nagayama S, Furutani E, Araki M, Imamura M.: How to control blood glucose under continuous glucose challenge. ASAIO J. 2003;49:237-242.
7. Galley P, Wagner R, Buck H, Weinert S, Bousamra S, Long J et al.: Use of subcutaneous glucose measurements to drive real-time algorithmdirected insulin infusion recommendations. Diabetes Technol Ther. 2004;6:245-246.
8. Renard E, Panteleon AE, Leong P, Han J, Kolopp M, Miller M et al. Effcacy of closed-loop control of blood glucose based on an implantable i.v. sensor and intraperitoneal pump. Diabetes. 2004;53:A114.
9. Sekigami T, Shimoda S, Nishida K, Matsuo Y, Ichimori S, Ichinose K, Shichiri M, Sakakida M, Araki E.: Comparison between closed-loop portal and peripheral venous insulin delivery systems for an artifcial endocrine pancreas. J Artif Organs. 2004;7:91-100.
10. Steil GM, Rebrin K, Hariri F, Chen Y, Darwin C, Saad M.: Continuous automated insulin delivery based on subcutaneous glucose sensing and an external insulin pump. Diabetes. 2004;53:A2.
11. Vering T.: Minimally invasive control loop system for SC-SC control on patients with type 1 diabetes. Diabetes Technol Ther. 2004;6:278.
12. Ward WK, Wood MD, Casey HM, Quinn MJ, Federiuk IF: An implantable subcutaneous glucose sensor array in ketosis-prone rats: closed-loop glycemic control. Artif Organs. 2005;29:131-143.
13. Parker RS, Doyle FJ 3rd, Peppas NA: A model-based algorithm for blood glucose control in type I diabetic patients. IEEE Trans Biomed Eng. 1999;46:148-157.
14. Gopakumaran B, Duman HM, Overholser DP, Federiuk IF, Quinn MJ, Wood MD, Ward WK.: A novel insulin delivery algorithm in rats with type 1 diabetes: the fading memory proportional-derivative method. Artif Organs. 2005;29:599-607.
15. Steil GM, Clark B, Kanderian S, Rebrin K: Modeling insulin action for development of a closed-loop artifcial pancreas. Diabetes Technol Ther. 2005;7:94-108.
16. XW, Chase JG, Shaw GM, Hann CE, Lotz T, Lin J, Singh-Levett I, Hollingsworth LJ, Wong OS, Andreassen S: Model predictive glycaemic regulation in critical illness using insulin and nutrition input: a pilot study. Med Eng Phys. 2006 28:665-681.
17. Wolpert HA: A clinician's perspective on some of the challenges in "closing the loop". Diabetes Technol Ther. 2003;5:843-846.
18. Code of Federal Regulations Title 40: Protection of Environment. Chapter I: Environmental Protection Agency. Subchapter C: Air Programs.
19. Steil GM, Rebrin K, Hariri F, Jinagonda S, Tadros S, Darwin C, Saad MF. Interstitial fuid glucose dynamics during insulin-induced hypoglycaemia. Diabetologia. 2005;48:1833-1840.
20. Rebrin K, Steil GM, Van Antwerp WP, Mastrototaro JJ. Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. Am J Physiol. 1999;277(3 Pt 1):E561-71.
21. Klonoff DC.: Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care. 2005;28:1231-1239.
22. Wilson DM, Block J: Real-time continuous glucose monitor use and patient selection: what have we learned and where are we going? Diabetes Technol Ther. 2005;7:788-791.
23. Bray GA.: Afferent signals regulating food intake. Proc Nutr Soc. 2000;59:373-384.
24. Catargi B.: Current status and future of implantable insulin pumps for the treatment of diabetes. Expert Rev Med Devices. 2004;1:181-185.
25. Weiss MA, Hua QX, Jia W, Nakagawa SH, Chu YC, Hu SQ, Katsoyannis PG.: Activities of monomeric insulin analogs at position A8 are uncorrelated with their thermodynamic stabilities. J Biol Chem. 2001;276:40018-40024.
26. Gin H, Renard E, Melki V, Boivin S, Schaepelynck-Belicar P, Guerci B, Selam JL, Brun JM, Riveline JP, Estour B, Catargi B; EVADIAC Study Group. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Diabetes Metab. 2003;29:602-607.
27. Eugster EA, Francis G; Lawson-Wilkins Drug and Therapeutics Committee. Position statement: Continuous subcutaneous insulin infusion in very young children with type 1 diabetes. Pediatrics. 2006;118:1244-1249.
28. Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, Plunkett CD, La Porte FB, Burke R, Brown MB, Halter JB, Raskin P. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28:1568-1573.
29. Bolli GB. Insulin treatment in type 1 diabetes. Endocr Pract. 2006;12 Suppl 1:105-109.
30. Steil GM, Rebrin K, Janowski R, Darwin C, Saad MF: Modeling betacell insulin secretion-implications for closed-loop glucose homeostasis. Diabetes Technol Ther. 2003;5:953-964.
31. Chase JG, Shaw GM, Lin J, Doran CV, Hann C, Robertson MB, Browne PM, Lotz T, Wake GC, Broughton B.: Adaptive bolus-based targeted glucose regulation of hyperglycaemia in critical care. Med Eng Phys. 2005;27:1-11.
32. Palerm CC, Willis JP, Desemone J, Bequette BW: Hypoglycemia prediction and detection using optimal estimation. Diabetes Technol Ther. 2005;7:3-14.
33. Knobbe EJ, Buckingham B.: The extended Kalman flter for continuous glucose monitoring. Diabetes Technol Ther. 2005;7:15-27.
34. Reach G.: Which Threshold to Detect Hypoglycemia?: Value of receiveroperator curve analysis to fnd a compromise between sensitivity and specifcity. Diabetes Care. 2001;24:803-804.
35. Bolli GB: Rational use of insulin analogues in the treatment of type 1 diabetes mellitus. Pediatr Endocrinol Rev. 2003;1:9-21.
36. Bequette BW: A critical assessment of algorithms and challenges in the development of a closed-loop artifcial pancreas. Diabetes Technol Ther. 2005;7:28-47.
37. Curry DL, Bennett LL, Grodsky GM: Dynamics of Insulin Secretion by the Perfused Rat Pancreas. Endocrinology. 1968;83:572-584.
38. Steil GM, Hwu CM, Janowski R, Hariri F, Jinagouda S, Darwin C, Tadros S, Rebrin K, Saad MF: Evaluation of insulin sensitivity and betacell function indexes obtained from minimal model analysis of a meal tolerance test. Diabetes. 2004;53:1201-1207.
39. Fabietti PG, Canonico V, OrsiniFederici M, Sarti E, MassiBenedetti M. Model based study on monitoring ketone bodies to improve safety in intensive insulin therapy. Int J Artif Organs. 2006;29:596-601.
40. Panteleon AE, Loutseiko M, Steil GM, Rebrin K. Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system. Diabetes. 2006;55:1995-2000.
41. Schlotthauer G, Gamero LG, Torres ME, Nicolini GA.: Modeling, identifcation and nonlinear model predictive control of type I diabetic patient. Med Eng Phys. 2006;28:240-250.
42. Ibbini MS, Masadeh MA.: A fuzzy logic based closed-loop control system for blood glucose level regulation in diabetics. J Med Eng Technol. 2005;29:64-69.
43. Kienitz HK, Yoneyama T.: A robust controller for insulin pumps based on H-infnity theory. IEEE Trans Biomed Eng. 1993;40:1133-1137.
44. Chee F, Savkin AV, Fernando TL, Nahavandi S.: Optimal H infnity insulin injection control for blood glucose regulation in diabetic patients. IEEE Trans Biomed Eng. 2005;52:1625-1631.
45. Kordella T.: New products. A pump/meter duo. Pump and meter talk via radio waves. Diabetes Forecast. 2003;56:45.
46. Wu P, Grainger DW: Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials. 2006;27:2450-67.
47. Weinzimer SA, Ruedy KJ, Tamborlane W V. Evaluation of factors affecting CGMS calibration. Diabetes Research In Children Network (Direcnet) Study Group; Buckingham BA, Kollman C, Beck R, Kalajian A, Fiallo-Scharer R, Tansey MJ, Fox LA, Wilson DM. Diabetes Technol Ther. 2006;8:318-325.
48. Nanda A, Nanda S, Ghilzai NM. Current developments using emerging transdermal technologies in physical enhancement methods. Curr Drug Deliv. 2006;3:233-242.
49. Bode B, Gross K, Rikalo N, Schwartz S, Wahl T, Page C, Gross T, Mastrototaro J. Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring system. Diabetes Technol Ther. 2004;6:105-113.
50. Piper HG, Alexander JL, Shukla A, Pigula F, Costello JM, Laussen PC, Jaksic T, Agus MS. Real-time continuous glucose monitoring in pediatric patients during and after cardiac surgery. Pediatrics. 2006;118:1176-1184.
51. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L: Improvement in Glycemic Excursions With a Transcutaneous, Real-Time Continuous Glucose Sensor: A randomized controlled trial. Diabetes Care. 2006;29:44-50.
52. Feldman B, Brazg R, Schwartz S, Weinstein R.: A continuous glucose sensor based on wired enzyme technology - results from a 3-day trial in patients with type 1 diabetes. Diabetes Technol Ther. 2003;5:769-779.
53. Nichols J, Klonoff D. The Need for Performance Standards for Continuous Glucose Monitors. J Diabetes Sci Technol. 2007;1:92-94
54. Pickup J, Keen H.: Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care. 2002;25:593-598.
55. Schaepelynck-Belicar P, Dufaitre-Patouraux L, Lassmann-Vague V.: What could be the reasons for giving up the implanted pump treatment? Diabetes Metab. 2005;31:87-89.
56. Gin H, Renard E, Melki V, Boivin S, Schaepelynck-Belicar P, Guerci B, Selam JL, Brun JM, Riveline JP, Estour B, Catargi B; EVADIAC Study Group.: Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Diabetes Metab. 2003;29:602-607.
57. Gin H, Melki V, Guerci B, Catargi B; EVADIAC Study Group.: Clinical Evaluation of a Newly Designed Compliant Side Port Catheter for an Insulin Implantable Pump: The EVADIAC experience, Diabetes Care. 2001;24:175.
58. Broussolle C, Jeandidier N, Hanaire-Broutin H.: French multicentre experience of implantable insulin pumps. The EVADIAC Study Group. Evaluation of Active Implants in Diabetes Society. Lancet. 1994;343:514-515.
59. Camacho RC, Pencek RR, Lacy DB, James FD, Wasserman DH.: Suppression of endogenous glucose production by mild hyperinsulinemia during exercise is determined predominantly by portal venous insulin. Diabetes. 2004;53:285-293.
60. Fisher LK, Halvorson M: Future developments in insulin pump therapy: progression from continuous subcutaneous insulin infusion to a sensorpump system. Diabetes Educ. 2006;32(Suppl 1):47S-52S.
61. Gross TM, Kayne D, King A, Rother C, Juth S.: A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technol Ther. 2003;5:365-369.
62. Cook CB, McMichael JP, Dunbar VG, Lieberman R. Description and preliminary evaluation of a Multiagent Intelligent Dosing System (MAIDS) to manage combination insulin-oral agent therapy in type 2 diabetes. Diabetes Technol Ther. 2005;7:937-947.
63. Garg SK, Schwartz S, Edelman SV.: Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care. 2004;27:734-738.
64. Klonoff DC: Serum fructosamine as a screening test for type 2 diabetes. Diabetes Technol Ther. 2000;2:537-539.
65. Gill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T, Sarno MJ.: Circulating 1, 5-anhydroglucitol levels in adult patients with diabetes refect longitudinal changes of glycemia: a U. S. trial of the GlycoMark assay. Diabetes Care. 2004;27:1859-1865.
66. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1cindependent risk factor for diabetic complications. JAMA. 2006;295:1707-1708.
67. Chassin LJ, Wilinska ME, Hovorka R.: Grading system to assess clinical performance of closed-loop glucose control. Diabetes Technol Ther. 2005;7:72-82.
68. Chase JG, Hann CE, Shaw GM, Wong J, Lin J, Lotz T, Le Compte A, Lonergan T: An Overview of Glycemic Control in Critical Care: Relating Performance and Clinical Results. J Diabetes Sci Technol. 2007;1:82-91
69. Kadish AH: Automation control of blood sugar: a servomechanism for glucose monitoring. Am J Med Electron. 1964;39:82-86.
70. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W.: An artifcial endocrine. Diabetes. 1974;23:389-396.
71. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W, Schipper H, Gander R.: Clinical control of diabetes by the artifcial pancreas. Diabetes. 1974;23:397-404.
72. Pfeiffer EF, Thum C, Clemens AH: The artifcial beta cell-a continuous control of blood sugar by external regulation of insulin infusion (glucose controlled insulin infusion system). Horm Metab Res. 1974;6:339-42.
73. Kawamori R, Shichiri M, Goriya Y, Yamasaki Y, Shigeta Y, Abe H.: Importance of insulin secretion based on the rate of change in blood glucose concentration in glucose tolerance, assessed by the artifcial beta cell. Acta Endocrinol (Copenh). 1978;87:339-351.
74. Shichiri M, Kawamori R, Abe H.: Normalization of the paradoxic secretion of glucagon in diabetics who were controlled by the artifcial beta cell. Diabetes. 1979;28:272-275.
75. Goriya Y, Kawamori R, Shichiri M, Abe H.: The development of an artifcial beta cell system and its validation in depancreatized dogs: the physiological restoration of blood glucose homeostasis. Med Prog Technol. 1979;6:99-108.
76. Yamasaki Y, Shichiri M, Kawamori R, Goriya Y, Sasai T, Morishima T, Nomura M, Tohdo R, Abe H.: Counterregulatory system in an artifcial endocrine pancreas. Glucose infusion algorithm. Artif Organs. 1979;3:265-270.
77. Heinemann L, Ampudia-Blasco FJ.: Glucose clamps with the Biostator: a critical reappraisal. Horm Metab Res. 1994;26:579-583.
78. Gin H, Catargi B, Rigalleau V, Rullier E, Roger P, Tabarin A.: Experience with the Biostator for diagnosis and assisted surgery of 21 insulinomas. Eur J Endocrinol. 1998;139:371-377.
79. Hovorka R, Chassin LJ, Wilinska ME, Canonico V, Akwi JA, Federici MO, Massi-Benedetti M, Hutzli I, Zaugg C, Kaufmann H, Both M, Vering T, Schaller HC, Schaupp L, Bodenlenz M, Pieber TR.: Closing the loop: the adicol experience. Diabetes Technol Ther. 2004;6:307-18.
80. Chassin LJ, Wilinska ME, Hovorka R.: Evaluation of glucose controllers in virtual environment: methodology and sample application. Artif Intell Med. 2004;32:171-181.
81. Wilinska ME, Chassin LJ, Schaller HC, Schaupp L, Pieber TR, Hovorka R.: Insulin kinetics in type-I diabetes: continuous and bolus delivery of rapid acting insulin. IEEE Trans Biomed Eng. 2005;52:3-12.
82. Hovorka R, Canonico V, Chassin LJ, Haueter U, Massi-Benedetti M, OrsiniFederici M, Pieber TR, Schaller HC, Schaupp L, Vering T, Wilinska ME: Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas. 2004;25:905-920.
83. Wilinska ME, Bodenlenz M, Chassin LJ, Schaller HC, Schaupp LA, Pieber TR, Hovorka R.: Interstitial glucose kinetics in subjects with type 1 diabetes under physiologic conditions. Metabolism. 2004;53:1484-1491.
84. Schaller HC, Bodenlenz M, Schaupp L, Plank J, Wach P, Pieber TR et al.: MPC algorithm controls blood glucose in patients with type 1 diabetes mellitus under fasting conditions using the IV-SC route. Diabetes Technol Ther. 2002;4:234.
85. Schaller HC, Schaupp LA, Bodenlenz M, Sommer R, Wutte A, Semlitsch B et al. Feasibility of the SC-SC route for an extracorporeal artifcial pancreas. Diabetes. 2002;51:462.
86. Schaller HC, Schaupp L, Bodenlenz M, Wilinska ME, Chassin LJ, Wach P et al. On-line adaptive algorithm with glucose prediction capacity for subcutaneous closed-loop control of glucose: evaluation under fasting conditions in patients with type 1 diabetes. Diabet Med. 2006;23:90-93.
87. Hovorka R.: Continuous glucose monitoring and closed-loop systems. Diabet Med. 2006;23:1-12.
88. Dudde R, Vering T, Piechotta G, Hintsche R. Computer-aided continuous drug infusion: setup and test of a mobile closed-loop system for the continuous automated infusion of insulin. IEEE Trans Inf Technol Biomed. 2006;10:395-402.
89. Hovorka R, Canonico V, Chassin LJ, Haueter U, Massi-Benedetti M, OrsiniFederici M, Pieber TR, Schaller HC, Schaupp L, Vering T, Wilinska ME: Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas. 2004;25:905-920.
90. Weinzimer SA, Steil GM, Kurtz N, Swan KL, Tamborlane WV: Automated feedback-controlled insulin delivery in children with tytpe 1 diabetes mellitus (T1D): a preliminary report. Diabetes. 2006;55:431-P.